CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RBBP9 (ImmuneEditome ID:10741)

1. Gene summary of enriched editing regions for RBBP9

check button Gene summary
Gene informationGene symbol

RBBP9

Gene ID

10741

GeneSynonymsBOG|RBBP10
GeneCytomap

20p11.23

GeneTypeprotein-coding
GeneDescriptionserine hydrolase RBBP9|B5T overexpressed gene protein|RBBP-10|RBBP-9|putative hydrolase RBBP9|retinoblastoma-binding protein 10|retinoblastoma-binding protein 9|retinoma-binding protein 9
GeneModificationdate20230329
UniprotIDO75884
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr20:18487644-18488587:-ENST00000337227.7ENSG00000089050.13RBBP9UTR3AluJr,AluSz6chr20:18487644-18488587:-.alignment


Top

2. Tumor-specific enriched editing regions for RBBP9


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr20:18487644-18488587:-BRCAEER1.6277e-52image
ENSG00000089050.13,RBBP9BRCAEAG1.6277e-52image
chr20:18487644-18488587:-COADEER1.0990e-03image
ENSG00000089050.13,RBBP9COADEAG1.0990e-03image
chr20:18487644-18488587:-HNSCEER1.2561e-06image
ENSG00000089050.13,RBBP9HNSCEAG1.2561e-06image
chr20:18487644-18488587:-KICHEER5.0799e-05image
ENSG00000089050.13,RBBP9KICHEAG5.0799e-05image
chr20:18487644-18488587:-KIRCEER1.4265e-02image
ENSG00000089050.13,RBBP9KIRCEAG1.4265e-02image
chr20:18487644-18488587:-KIRPEER5.4546e-05image
ENSG00000089050.13,RBBP9KIRPEAG5.4546e-05image
chr20:18487644-18488587:-LIHCEER1.4234e-02image
ENSG00000089050.13,RBBP9LIHCEAG1.4234e-02image
chr20:18487644-18488587:-LUADEER7.9967e-10image
ENSG00000089050.13,RBBP9LUADEAG7.9967e-10image
chr20:18487644-18488587:-PRADEER4.0948e-04image
ENSG00000089050.13,RBBP9PRADEAG4.0948e-04image
chr20:18487644-18488587:-THCAEER7.7225e-03image
ENSG00000089050.13,RBBP9THCAEAG7.7225e-03image
chr20:18487644-18488587:-UCECEER1.7378e-03image
ENSG00000089050.13,RBBP9UCECEAG1.7378e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr20:18487644-18488587:-TGCTPathEER2.9834e-029.6875e-03-0.2841image
ENSG00000089050.13,RBBP9TGCTPathEAG2.9834e-029.6875e-03-0.2841image
ENSG00000089050.13,RBBP9UCSCliEAG2.0735e-022.5744e-03-0.3986image
chr20:18487644-18488587:-UCSCliEER2.0735e-022.5744e-03-0.3986image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for RBBP9


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr20:18487644-18488587:-BLCAEERENSG00000059378,PARP120.43282.7701e-162.0188e-180.4208imageNCNBP;DDX3X;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;FXR2;NOP58;RBFOX2;SRSF9NAT_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr20:18487644-18488587:-BLCAEERENSG00000068079,IFI350.42432.2244e-153.3918e-200.4402imageNDDX3X;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR2;LIN28;NOP58;RBFOX2;SRSF9IFI35T_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr20:18487644-18488587:-BLCAEERENSG00000010030,ETV70.39242.8158e-131.8038e-170.4098imageNEIF4A3;ELAVL1;FBL;FUS;NOP58;RBFOX2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr20:18487644-18488587:-BRCAEERENSG00000068079,IFI350.47343.5544e-561.5754e-500.4333imageNDDX3X;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR2;LIN28;NOP58;RBFOX2;SRSF9IFI35T_cells_regulatory_(Tregs)GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr20:18487644-18488587:-BRCAEERENSG00000160710,ADAR0.46242.8200e-532.6571e-600.4701imageNCNBP;DDX3X;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;FXR2;LIN28;NOP58;RBFOX2;RBM5;SRSF9ADARMacrophages_M1GSVA_HALLMARK_MITOTIC_SPINDLE
chr20:18487644-18488587:-BRCAEERENSG00000108771,DHX580.44586.3875e-498.0793e-480.4223imageNDDX3X;EIF4A3;ELAVL1;FBL;FUS;FXR2;RBFOX2DHX58T_cells_regulatory_(Tregs)GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr20:18487644-18488587:-BRCAEERENSG00000089127,OAS10.44081.3400e-471.2384e-470.4215imageNEIF4A3;FUS;SRSF9OAS1Macrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr20:18487644-18488587:-BRCAEERENSG00000138496,PARP90.41921.5454e-426.4642e-440.4056imageNCNBP;DDX3X;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR2;NOP58;RBFOX2;SRSF9NAMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr20:18487644-18488587:-BRCAEERENSG00000152778,IFIT50.40191.5099e-381.3699e-460.4172imageNCNBP;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;FXR2;LIN28;NOP58IFIT5Macrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr20:18487644-18488587:-LIHCEERENSG00000126457,PRMT1-0.51261.6572e-191.1856e-18-0.4431imageNCNBP;DDX3X;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR2;LIN28;NOP58;RBFOX2;RBM5;SRSF9PRMT1Macrophages_M0GSVA_HALLMARK_BILE_ACID_METABOLISM

More results



Top

4. Enriched editing regions and immune related splicing for RBBP9


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr20:18487644-18488587:-
BLCAEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.55604.2994e-277.0618e-26-0.4951imageNCNBP;DDX3X;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;FXR2;LIN28;NOP58;RBFOX2;RBM5;SRSF9PRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000089050.13,RBBP9
BLCAEAGIRENSG00000177225.12chr11767224:770398:771332:771370-0.20942.4831e-044.2797e-18-0.4195imageNADAR;AUH;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM47;RNF219;SF3A3;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;ZNF184NAT_cells_CD8GSVA_HALLMARK_MYC_TARGETS_V2
chr20:18487644-18488587:-
BLCAEERIRENSG00000177225.12chr11767224:770398:771332:771370-0.20942.0417e-044.2797e-18-0.4195imageNCNBP;DDX3X;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR2;LIN28;NOP58;RBFOX2;SRSF9NAT_cells_CD8GSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000089050.13,RBBP9
BLCAEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.55604.4136e-277.0618e-26-0.4951imageNADAR;AUH;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;PUM2;RBFOX2;RBM10;RBM47;RNF219;SF3A3;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184PRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr20:18487644-18488587:-
BRCAEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.44404.5068e-472.7538e-52-0.4414imageNCNBP;DDX3X;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;FXR2;LIN28;NOP58;RBFOX2;RBM5;SRSF9PRKCSHT_cells_regulatory_(Tregs)GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000089050.13,RBBP9
BRCAEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.44404.2283e-482.7538e-52-0.4414imageNADAR;AUH;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;PUM2;RBFOX2;RBM10;RBM47;RNF219;SF3A3;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184PRKCSHT_cells_regulatory_(Tregs)GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000089050.13,RBBP9
CESCEAGIRENSG00000165055.11chr7128500902:128501832:128502613:128502832-0.38212.4024e-072.9535e-13-0.4054imageNADAR;AUH;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM47;RNF219;SF3A3;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr20:18487644-18488587:-
CESCEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.46476.3230e-123.1355e-16-0.4482imageNCNBP;DDX3X;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;FXR2;LIN28;NOP58;RBFOX2;RBM5;SRSF9PRKCSHMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000089050.13,RBBP9
CESCEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.46475.0225e-123.1355e-16-0.4482imageNADAR;AUH;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;PUM2;RBFOX2;RBM10;RBM47;RNF219;SF3A3;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184PRKCSHMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr20:18487644-18488587:-
CESCEERIRENSG00000165055.11chr7128500902:128501832:128502613:128502832-0.38213.8710e-072.9535e-13-0.4054imageNCNBP;DDX3X;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;FXR2;LIN28;NOP58;RBFOX2;RBM5;SRSF9NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

5. Enriched editing regions and immune infiltration for RBBP9


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr20:18487644-18488587:-ACCEERT_cells_CD4_memory_activated4.7062e-020.2256image
ENSG00000089050.13,RBBP9ACCEAGT_cells_CD4_memory_activated4.7062e-020.2256image
chr20:18487644-18488587:-BLCAEERT_cells_CD4_memory_activated2.2291e-050.2114image
ENSG00000089050.13,RBBP9BLCAEAGT_cells_CD4_memory_activated2.2291e-050.2114image
chr20:18487644-18488587:-BRCAEERT_cells_regulatory_(Tregs)3.4762e-060.1409image
ENSG00000089050.13,RBBP9BRCAEAGT_cells_regulatory_(Tregs)3.4762e-060.1409image
chr20:18487644-18488587:-CESCEERB_cells_naive6.0343e-03-0.1582image
ENSG00000089050.13,RBBP9CESCEAGB_cells_naive6.0343e-03-0.1582image
chr20:18487644-18488587:-CHOLEERB_cells_memory1.7972e-020.3978image
ENSG00000089050.13,RBBP9CHOLEAGB_cells_memory1.7972e-020.3978image
chr20:18487644-18488587:-COADEEREosinophils3.6151e-020.1276image
ENSG00000089050.13,RBBP9COADEAGEosinophils3.6151e-020.1276image
chr20:18487644-18488587:-DLBCEERMast_cells_resting2.0585e-020.3481image
ENSG00000089050.13,RBBP9DLBCEAGMast_cells_resting2.0585e-020.3481image
chr20:18487644-18488587:-ESCAEERMacrophages_M29.3214e-040.2584image
ENSG00000089050.13,RBBP9ESCAEAGMacrophages_M29.3214e-040.2584image
chr20:18487644-18488587:-GBMEERMacrophages_M11.2687e-040.2931image
ENSG00000089050.13,RBBP9GBMEAGMacrophages_M11.2687e-040.2931image
chr20:18487644-18488587:-HNSCEERMacrophages_M12.0940e-040.1662image
ENSG00000089050.13,RBBP9HNSCEAGMacrophages_M12.0940e-040.1662image
chr20:18487644-18488587:-KICHEERNK_cells_resting1.6780e-020.3003image
ENSG00000089050.13,RBBP9KICHEAGNK_cells_resting1.6780e-020.3003image
chr20:18487644-18488587:-KIRCEERT_cells_gamma_delta1.1606e-070.2668image
ENSG00000089050.13,RBBP9KIRCEAGT_cells_gamma_delta1.1606e-070.2668image
chr20:18487644-18488587:-KIRPEERT_cells_CD4_memory_resting3.4881e-04-0.2104image
ENSG00000089050.13,RBBP9KIRPEAGT_cells_CD4_memory_resting3.4881e-04-0.2104image
ENSG00000089050.13,RBBP9LAMLEAGMacrophages_M01.0703e-020.3447image
chr20:18487644-18488587:-LGGEERMacrophages_M11.7730e-060.2060image
ENSG00000089050.13,RBBP9LGGEAGMacrophages_M11.7730e-060.2060image
chr20:18487644-18488587:-LIHCEERMacrophages_M12.4496e-050.2210image
ENSG00000089050.13,RBBP9LIHCEAGMacrophages_M12.4496e-050.2210image
chr20:18487644-18488587:-LUADEERT_cells_CD81.0107e-030.1460image
ENSG00000089050.13,RBBP9LUADEAGT_cells_CD81.0107e-030.1460image
chr20:18487644-18488587:-LUSCEERT_cells_CD85.5623e-090.2580image
ENSG00000089050.13,RBBP9LUSCEAGT_cells_CD85.5623e-090.2580image
chr20:18487644-18488587:-MESOEERDendritic_cells_activated2.0414e-050.4706image
ENSG00000089050.13,RBBP9MESOEAGDendritic_cells_activated2.0414e-050.4706image
chr20:18487644-18488587:-OVEERT_cells_CD83.0808e-060.2696image
ENSG00000089050.13,RBBP9OVEAGT_cells_CD83.0808e-060.2696image
chr20:18487644-18488587:-PAADEERB_cells_naive4.9697e-02-0.1473image
ENSG00000089050.13,RBBP9PAADEAGB_cells_naive4.9697e-02-0.1473image
chr20:18487644-18488587:-PCPGEERMacrophages_M17.5909e-050.2922image
ENSG00000089050.13,RBBP9PCPGEAGMacrophages_M17.5909e-050.2922image
chr20:18487644-18488587:-PRADEERT_cells_CD4_naive9.1199e-110.2865image
ENSG00000089050.13,RBBP9PRADEAGT_cells_CD4_naive9.1199e-110.2865image
chr20:18487644-18488587:-READEERMast_cells_resting5.3168e-030.2899image
ENSG00000089050.13,RBBP9READEAGMast_cells_resting5.3168e-030.2899image
chr20:18487644-18488587:-SARCEERT_cells_CD83.6378e-030.1822image
ENSG00000089050.13,RBBP9SARCEAGT_cells_CD83.6378e-030.1822image
chr20:18487644-18488587:-SKCMEERT_cells_CD82.1890e-080.2586image
ENSG00000089050.13,RBBP9SKCMEAGT_cells_CD82.1890e-080.2586image
chr20:18487644-18488587:-STADEERT_cells_CD4_memory_activated1.2290e-040.1986image
ENSG00000089050.13,RBBP9STADEAGT_cells_CD4_memory_activated1.2290e-040.1986image
chr20:18487644-18488587:-TGCTEERMacrophages_M21.4529e-11-0.5084image
ENSG00000089050.13,RBBP9TGCTEAGMacrophages_M21.4529e-11-0.5084image
chr20:18487644-18488587:-THCAEERT_cells_regulatory_(Tregs)3.0628e-070.2257image
ENSG00000089050.13,RBBP9THCAEAGT_cells_regulatory_(Tregs)3.0628e-070.2257image
chr20:18487644-18488587:-THYMEERB_cells_memory3.9180e-030.2682image
ENSG00000089050.13,RBBP9THYMEAGB_cells_memory3.9180e-030.2682image
chr20:18487644-18488587:-UCECEERDendritic_cells_activated5.5516e-030.2106image
ENSG00000089050.13,RBBP9UCECEAGDendritic_cells_activated5.5516e-030.2106image
chr20:18487644-18488587:-UVMEERMast_cells_activated3.4733e-020.3121image
ENSG00000089050.13,RBBP9UVMEAGMast_cells_activated3.4733e-020.3121image


Top

6. Enriched editing regions and immune gene sets for RBBP9


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr20:18487644-18488587:-BRCAEER1.9727e-04image3.6089e-05-0.1255image
ENSG00000089050.13,RBBP9BRCAEAG1.9727e-04image3.6089e-05-0.1255image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr20:18487644-18488587:-ACCGSVA_HALLMARK_DNA_REPAIREER1.7984e-02-0.2673image
ENSG00000089050.13,RBBP9ACCGSVA_HALLMARK_DNA_REPAIREAG1.7984e-02-0.2673image
ENSG00000089050.13,RBBP9BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5586e-120.3453image
chr20:18487644-18488587:-BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5586e-120.3453image
ENSG00000089050.13,RBBP9BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.1145e-340.3605image
chr20:18487644-18488587:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.1145e-340.3605image
ENSG00000089050.13,RBBP9CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.1169e-120.3956image
chr20:18487644-18488587:-CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1169e-120.3956image
ENSG00000089050.13,RBBP9CHOLGSVA_HALLMARK_SPERMATOGENESISEAG3.2500e-03-0.4836image
chr20:18487644-18488587:-CHOLGSVA_HALLMARK_SPERMATOGENESISEER3.2500e-03-0.4836image
ENSG00000089050.13,RBBP9COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG9.8267e-08-0.3174image
chr20:18487644-18488587:-COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER9.8267e-08-0.3174image
chr20:18487644-18488587:-DLBCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.8519e-03-0.4171image
ENSG00000089050.13,RBBP9DLBCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.8519e-03-0.4171image
ENSG00000089050.13,RBBP9ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4919e-070.3998image
chr20:18487644-18488587:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4919e-070.3998image
chr20:18487644-18488587:-GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.4207e-100.4536image
ENSG00000089050.13,RBBP9GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.4207e-100.4536image
chr20:18487644-18488587:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.1259e-120.3015image
ENSG00000089050.13,RBBP9HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.1259e-120.3015image
chr20:18487644-18488587:-KICHGSVA_HALLMARK_TGF_BETA_SIGNALINGEER9.2878e-03-0.3253image
ENSG00000089050.13,RBBP9KICHGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG9.2878e-03-0.3253image
ENSG00000089050.13,RBBP9KIRCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.5885e-09-0.3021image
chr20:18487644-18488587:-KIRCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.5885e-09-0.3021image
ENSG00000089050.13,RBBP9KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.4195e-09-0.3329image
chr20:18487644-18488587:-KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER8.4195e-09-0.3329image
ENSG00000089050.13,RBBP9LAMLGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.5387e-02-0.3282image
ENSG00000089050.13,RBBP9LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.8104e-230.4109image
chr20:18487644-18488587:-LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.8104e-230.4109image
chr20:18487644-18488587:-LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER6.0894e-140.3828image
ENSG00000089050.13,RBBP9LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG6.0894e-140.3828image
chr20:18487644-18488587:-LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.9601e-090.2632image
ENSG00000089050.13,RBBP9LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9601e-090.2632image
chr20:18487644-18488587:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.0167e-120.3024image
ENSG00000089050.13,RBBP9LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.0167e-120.3024image
chr20:18487644-18488587:-MESOGSVA_HALLMARK_APICAL_JUNCTIONEER4.0978e-04-0.3977image
ENSG00000089050.13,RBBP9MESOGSVA_HALLMARK_APICAL_JUNCTIONEAG4.0978e-04-0.3977image
ENSG00000089050.13,RBBP9OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.8001e-170.4654image
chr20:18487644-18488587:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.8001e-170.4654image
ENSG00000089050.13,RBBP9PAADGSVA_HALLMARK_UV_RESPONSE_DNEAG2.7980e-05-0.3085image
chr20:18487644-18488587:-PAADGSVA_HALLMARK_UV_RESPONSE_DNEER2.7980e-05-0.3085image
ENSG00000089050.13,RBBP9PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.6693e-050.2943image
chr20:18487644-18488587:-PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.6693e-050.2943image
chr20:18487644-18488587:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER1.5402e-07-0.2337image
ENSG00000089050.13,RBBP9PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.5402e-07-0.2337image
chr20:18487644-18488587:-READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.0540e-020.2669image
ENSG00000089050.13,RBBP9READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.0540e-020.2669image
chr20:18487644-18488587:-SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.5096e-080.3302image
ENSG00000089050.13,RBBP9SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.5096e-080.3302image
ENSG00000089050.13,RBBP9SKCMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.4027e-070.2393image
chr20:18487644-18488587:-SKCMGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.4027e-070.2393image
ENSG00000089050.13,RBBP9STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4735e-110.3419image
chr20:18487644-18488587:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4735e-110.3419image
ENSG00000089050.13,RBBP9TGCTGSVA_HALLMARK_ANGIOGENESISEAG9.0545e-08-0.4133image
chr20:18487644-18488587:-TGCTGSVA_HALLMARK_ANGIOGENESISEER9.0545e-08-0.4133image
chr20:18487644-18488587:-THCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.9627e-10-0.2785image
ENSG00000089050.13,RBBP9THCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.9627e-10-0.2785image
ENSG00000089050.13,RBBP9THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG9.2255e-07-0.4407image
chr20:18487644-18488587:-THYMGSVA_HALLMARK_MITOTIC_SPINDLEEER9.2255e-07-0.4407image
chr20:18487644-18488587:-UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.4756e-07-0.3812image
ENSG00000089050.13,RBBP9UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.4756e-07-0.3812image
ENSG00000089050.13,RBBP9UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.7284e-020.3199image
chr20:18487644-18488587:-UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.7284e-020.3199image
chr20:18487644-18488587:-UVMGSVA_HALLMARK_MYOGENESISEER2.2318e-030.4397image
ENSG00000089050.13,RBBP9UVMGSVA_HALLMARK_MYOGENESISEAG2.2318e-030.4397image


Top

7. Enriched editing regions and drugs for RBBP9


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr20:18487644-18488587:-ACCAZD8055EER7.9838e-030.2983image
ENSG00000089050.13,RBBP9ACCAZD8055EAG7.9838e-030.2983image
ENSG00000089050.13,RBBP9BLCAFH535EAG1.2569e-100.3159image
chr20:18487644-18488587:-BLCAFH535EER1.2569e-100.3159image
ENSG00000089050.13,RBBP9BRCACHIR.99021EAG1.6155e-110.2035image
chr20:18487644-18488587:-BRCACHIR.99021EER1.6155e-110.2035image
ENSG00000089050.13,RBBP9CESCCI.1040EAG3.2922e-13-0.4040image
chr20:18487644-18488587:-CESCCI.1040EER3.2922e-13-0.4040image
ENSG00000089050.13,RBBP9CHOLDocetaxelEAG2.3880e-020.3812image
chr20:18487644-18488587:-CHOLDocetaxelEER2.3880e-020.3812image
ENSG00000089050.13,RBBP9COADBMS.708163EAG1.1649e-06-0.2908image
chr20:18487644-18488587:-COADBMS.708163EER1.1649e-06-0.2908image
chr20:18487644-18488587:-DLBCImatinibEER3.6490e-020.3163image
ENSG00000089050.13,RBBP9DLBCImatinibEAG3.6490e-020.3163image
ENSG00000089050.13,RBBP9ESCAAG.014699EAG2.0437e-030.2413image
chr20:18487644-18488587:-ESCAAG.014699EER2.0437e-030.2413image
chr20:18487644-18488587:-GBMBIBW2992EER3.2597e-10-0.4633image
ENSG00000089050.13,RBBP9GBMBIBW2992EAG3.2597e-10-0.4633image
chr20:18487644-18488587:-HNSCKU.55933EER3.4337e-11-0.2926image
ENSG00000089050.13,RBBP9HNSCKU.55933EAG3.4337e-11-0.2926image
chr20:18487644-18488587:-KICHABT.263EER8.3802e-030.3294image
ENSG00000089050.13,RBBP9KICHABT.263EAG8.3802e-030.3294image
ENSG00000089050.13,RBBP9KIRCBexaroteneEAG9.7750e-110.3228image
chr20:18487644-18488587:-KIRCBexaroteneEER9.7750e-110.3228image
ENSG00000089050.13,RBBP9KIRPFTI.277EAG1.4558e-100.3679image
chr20:18487644-18488587:-KIRPFTI.277EER1.4558e-100.3679image
ENSG00000089050.13,RBBP9LAMLJNK.Inhibitor.VIIIEAG2.3402e-030.4057image
ENSG00000089050.13,RBBP9LGGAxitinibEAG2.5017e-290.4620image
chr20:18487644-18488587:-LGGAxitinibEER2.5017e-290.4620image
chr20:18487644-18488587:-LIHCBMS.754807EER2.4532e-210.4740image
ENSG00000089050.13,RBBP9LIHCBMS.754807EAG2.4532e-210.4740image
chr20:18487644-18488587:-LUADAxitinibEER1.2419e-040.1701image
ENSG00000089050.13,RBBP9LUADAxitinibEAG1.2419e-040.1701image
chr20:18487644-18488587:-LUSCAP.24534EER4.3908e-060.2045image
ENSG00000089050.13,RBBP9LUSCAP.24534EAG4.3908e-060.2045image
chr20:18487644-18488587:-MESOBexaroteneEER1.6298e-040.4219image
ENSG00000089050.13,RBBP9MESOBexaroteneEAG1.6298e-040.4219image
ENSG00000089050.13,RBBP9OVEmbelinEAG7.4257e-120.3874image
chr20:18487644-18488587:-OVEmbelinEER7.4257e-120.3874image
ENSG00000089050.13,RBBP9PAADJNJ.26854165EAG7.9215e-060.3278image
chr20:18487644-18488587:-PAADJNJ.26854165EER7.9215e-060.3278image
ENSG00000089050.13,RBBP9PCPGAZD6482EAG1.5549e-060.3510image
chr20:18487644-18488587:-PCPGAZD6482EER1.5549e-060.3510image
chr20:18487644-18488587:-PRADDMOGEER1.6261e-120.3110image
ENSG00000089050.13,RBBP9PRADDMOGEAG1.6261e-120.3110image
chr20:18487644-18488587:-READMidostaurinEER8.1311e-030.2758image
ENSG00000089050.13,RBBP9READMidostaurinEAG8.1311e-030.2758image
chr20:18487644-18488587:-SARCAG.014699EER1.0528e-070.3267image
ENSG00000089050.13,RBBP9SARCAG.014699EAG1.0528e-070.3267image
ENSG00000089050.13,RBBP9SKCMAZD6244EAG5.0749e-13-0.3300image
chr20:18487644-18488587:-SKCMAZD6244EER5.0749e-13-0.3300image
ENSG00000089050.13,RBBP9STADCI.1040EAG5.3318e-09-0.2979image
chr20:18487644-18488587:-STADCI.1040EER5.3318e-09-0.2979image
ENSG00000089050.13,RBBP9TGCTFTI.277EAG6.1021e-090.4459image
chr20:18487644-18488587:-TGCTFTI.277EER6.1021e-090.4459image
chr20:18487644-18488587:-THCAEmbelinEER2.7189e-190.3854image
ENSG00000089050.13,RBBP9THCAEmbelinEAG2.7189e-190.3854image
ENSG00000089050.13,RBBP9THYMEmbelinEAG2.8940e-080.4911image
chr20:18487644-18488587:-THYMEmbelinEER2.8940e-080.4911image
chr20:18487644-18488587:-UCECAZD6244EER3.0792e-05-0.3121image
ENSG00000089050.13,RBBP9UCECAZD6244EAG3.0792e-05-0.3121image
ENSG00000089050.13,RBBP9UCSCEP.701EAG1.5802e-02-0.3240image
chr20:18487644-18488587:-UCSCEP.701EER1.5802e-02-0.3240image
chr20:18487644-18488587:-UVMGSK269962AEER4.2363e-04-0.4984image
ENSG00000089050.13,RBBP9UVMGSK269962AEAG4.2363e-04-0.4984image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType